Clinical Trial Update: APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for APRIL CAR T cells (AUTO2) targeting BCMA and TACI in multiple myeloma; trial status terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• APRIL CAR T cells (AUTO2) (APRIL CAR T cells (AUTO2))

Snippet

Sponsor: Autolus Limited | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-23